Market research
4883.TSE Modalis Therapeutics Corporation
TSE JPY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 900
- Dividend yield
- Not available
- Beta
- 0.41
Profile
Instrument facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- JP3922600006
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 900
- Dividend yield
- Not available
- Beta
- 0.41
About
About Modalis Therapeutics Corporation
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
Research context
Modalis Therapeutics Corporation appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the 4883.TSE discussion.
No comments yet
Start a focused discussion about 4883.TSE.